AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02940405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo given as a tablet one hour before staring the root canal treatment
Study NCT01893931 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ED Discharge & Medication Call
Description: Patients will receive a follow up phone call from a nurse to review discharge instructions and provide any necessary patient navigation.
Study NCT01893931 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Study NCT04200885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen Trometamol
Description: Patients were instructed to record the number of drugs they used until the second and seventh postoperative days.
Study NCT04200885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 21-Phosphate
Description: Injections were administered in the immediate preoperative period as a single shot.
Study NCT04200885 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Elastic Bandage
Description: The bands' lengths were individually measured and divided into five equal parts up to 2/3 of their lengths to obtain fan-type shape.
Study NCT04628351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bladder Training
Description: Patients in the structured bladder training group were trained on lifestyle changes (nutrition, fluid management, exercise), pelvic floor muscle exercises and bladder control techniques.
Study NCT00596427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam HCL
Description: Colesevelam HCL 625 mg: 3 tablets twice per day
Study NCT00596427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets: 3 tablets twice per day
Study NCT00599911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA24530
Description: per oral, once daily for 6 weeks
Study NCT00599911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: per oral, once daily for 6 weeks
Study NCT00599911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: per oral, once daily for 6 weeks
Study NCT03187691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Encochleated Amphotericin B (CAMB)
Description: Lipid-crystal nano-particle formulation amphotericin B
Study NCT02112331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raw human milk
Study NCT02112331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pasteurized human milk
Study NCT02112331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pasteurized-homogenized human milk
Study NCT02112331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gastric samples
Study NCT01823692 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ultrasonography
Description: after manipulation and reduction were performed by single emergency medicine specialist under Bier block regional anesthesia or procedural sedation-analgesia, The ultrasonography was performed by the single emergency department physician in a long axis both in a anterioposterior and lateral views in determining whether the distal and proximal distal to a fracture was in a straight line (less than 3 mm difference) or not?
Study NCT03383120 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser treatment
Description: Laser treatment of the peri-implantitis lesion includes mechanical debridement of the implant using an ultrasonic device and plastic curettes followed by diode laser sub-mucosal application for 90 seconds. This is repeated two more times at one-week intervals.
Study NCT03383120 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment with adjunctive systemic antibiotics
Description: Mechanical debridement of the implant will be done in a similar manner to the test group (without laser application) followed by open flap debridement 2 weeks after, and post-operative prescription of Amoxicillin and Metronidazole systemic antibiotics 3 times per day for a period of 1 week
Study NCT02323282 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ropivacaine
Study NCT04004247 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal generator (AirVO2)
Description: High Flow Nasal Oxygenation
Study NCT03273556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aliaxin® EV Essential Volume (IBSA Farmaceutici Italia S.r.l.) with Lidocaine 0.3%
Description: The injective treatment was performed, during T0 visit after the basal evaluations, mono-laterally on nasolabial fold,(right or left face side in according to a previously defined randomisation list).~A quantity of Aliaxin® Ev (up to a maximum of 0.5 ml) with Lidocaine 0.3% was injected on the nasolabial fold to achieve the aesthetic correction of the skin defect.
Study NCT03273556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aliaxin® EV Essential Volume (IBSA Farmaceutici Italia S.r.l.)
Description: The injective treatment was performed on the contralateral nasolabial fold during T0 visit, after the basal evaluations .~A quantity of Aliaxin® Ev up to a maximum of 0.5 ml was injected on the nasolabial fold to achieve the aesthetic correction of the skin defect.
Study NCT01874301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High quantity probiotic
Description: The intervention type is food product
Study NCT01874301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low quantity probiotic
Description: The intervention type is food product
Study NCT01874301 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00852540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retpamulin Ointment, 1%
Description: Topical retapamulin (SB-275833) ointment, 1% (w/w), and placebo ointment, will be provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse-taper puncture-tip caps. Retapamulin or placebo ointment will be applied twice daily for 5 days.
Study NCT00852540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Adult and adolescent (=>12 years of age) subjects will receive one 600mg linezolid tablet (overencapsulated), or one placebo capsule, twice daily for 10 days. Pediatric subjects aged 5-11 years will receive 10mg/kg body weight of a 100mg/5mL oral linezolid suspension, or placebo suspension, twice daily for 10 days. Pediatric subjects \<5 years of age will receive 10mg/kg of a 100mg/5mL oral linezolid suspension, or placebo suspension, three times daily for 10 days.
Study NCT05102604 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Avocado
Description: Subjects will eat one avocado in addition to their usual diet
Study NCT05102604 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Habitual diet
Description: Subjects will eat their usual diet
Study NCT03620370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normobaric oxygen therapy
Description: In this study, it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours. This therapy start should in Pre-hospital or emergency room as early as possible after diagnosed ischemic stroke and uninterrupted during other treatments including mechanical thrombolytic therapy and standard clinical treatment.
Study NCT01503203 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength Training
Description: It will be does three times per week. The exercises are: squat, single leg squat, leg extension, leg curl, chair adductor, chair abductor and double plantar flexion.
Study NCT01503203 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core training
Description: Exercises for trunk stabilization. Will be lateral, front and back bridges. It will be does three times per week with three sets between fifteen and third seconds.
Study NCT01503203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Virtual Training
Description: The video game (Nintendo Wii and Wii Balance Board) will used for intervention. After strength and core training will be applied the physical virtual training during thirty minutes. Tho total time session for the Wii Group will be 110 minutes.
Study NCT01503203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training
Description: It will be does three times per week. The exercises are: squat, single leg squat, leg extension, leg curl, chair adductor, chair abductor and double plantar flexion.
Study NCT01503203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Training
Description: Exercises for trunk stabilization. Will be lateral, front and back bridges. It will be does three times per week with three sets between fifteen and third seconds.
Study NCT01008020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: tea catechin extracts
Description: Tea catechin extracts 540 mg/day, are consumed for 5 months.
Study NCT03324269 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NOL
Description: After tracheal intubation, a Tetanus test (60 mAmp,100 Hz) is done during 30 sec at remifentanil level Ce of 4 ng/ml (with starting NOL value \<10). According to the NOL response: increment of 1 ng/ml of RemiCe if NOL gradient ≥ 20 / decrement of 1 ng/ml of remifentanil Ce NOL gradient \< 10. During the testing period propofol Ce is fixed at the concentration associated with BIS levels between 45-60 during the first calibration.~Upon the incision and 2 minutes after skin incision, Propofol TCI (Schnider model) is adjusted to BIS between 45-60 and remifentanil Ce at which the variation of NOL index variation is less than10 units at a NOL starting value \<10. MAP (mean arterial pressure), HR (heart rhythm) and NIBP (non-invasive blood pressure) will be measured.~The formula derived from the calibration phase will be tested during a single tetanic stimulation at remifentanil Ce of 4 ng/ml during the validation phase.
Study NCT03924050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TORIPALIMAB INJECTION(JS001 )
Description: TORIPALIMAB INJECTION(JS001 ) or Placebo, 240mg/6ml/vial, Q3W,up to 2 years of treatment.
Study NCT03924050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TORIPALIMAB INJECTION(JS001 )
Description: TORIPALIMAB INJECTION(JS001 ) or Placebo, 240mg/6ml/vial, Q3W,up to 2 years of treatment.
Study NCT03711968 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitative treatment protocol
Description: A combination of: postural exercise with visual spatial tasks, relaxation, balance exercise, motricity improvement and cognitive rehabilitation.
Study NCT02147639 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium Nitrate
Study NCT02147639 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium Nitrate - double dose
Study NCT02147639 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02147639 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Increased exercise intensity
Study NCT04197245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline injection therapy in post-acne atrophic scars
Description: saline injection contains 0.9% isotonic sodium chloride solution
Study NCT01584375 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Flat midline head position
Description: Infant's chin will be kept at a 90±5 degree angle to the bed (the chin and nose being in line with the sternum) throughout the first 168 hours of life.~--------------------------------------------------------------------------------
Study NCT01584375 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Right flat lateral head position
Description: Infant's head will be tilted 85-90 degrees to right side (approximately the entire chin beyond the right nipple line) throughout the first 168 hours of life.
Study NCT00944853 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid zinc syrup
Description: Liquid zinc syrup containing 5 mg zinc as zinc sulfate
Study NCT00944853 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc tablet
Description: Dispersible zinc tablet containing 5 mg zinc
Study NCT00944853 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Liquid placebo supplement
Description: Liquid placebo supplement containing 0 mg zinc
Study NCT03149562 — intervention group
Intervention type: DRUG
Intervention: plasma transfusions
Description: These critical ill neonates with plasma transfusions
Study NCT03149562 — intervention group
Intervention type: DRUG
Intervention: non-plasma transfusions
Description: These critical ill neonates without plasma transfusions
Study NCT01046396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adapalene cream 0.1% and adapalene lotion 0.1%
Description: adapalene cream 0.1% - apply once daily on one side of the face for 3 weeks
Study NCT01046396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adapalene lotion 0.1%
Description: adapalene lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks
Study NCT02435992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPC1063
Study NCT02435992 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02638194 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active smoking of Tobacco Hookah for 2 hours
Study NCT03244085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL-007 tablet
Description: Patients will be enrolled in 1 of 3 cohorts (6 patients per cohort): QL 007 200 mg/day (100 mg BID), or QL 007 400 mg/day (200 mg/BID), or QL 007 600 mg QD. QL 007 will be administered orally daily over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
Study NCT02638194 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to tobacco hookah second hand smoke
Study NCT02638194 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visit a win bar
Description: Participants will visit a wine bar for food and/or drinks
Study NCT03052270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arabin Pessary
Description: Insertion of Arabin pessary for the prevention of preterm delivery
Study NCT03052270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arabin Pessary
Description: Insertion of Arabin pessary for the prevention of preterm delivery
Study NCT03530215 — intervention group
Intervention type: DRUG
Intervention: Antineoplastic and Immunomodulating Agents
Description: Antineoplastic agents, endocrine therapy, immunostimulants and immunosuppressants drugs included in the ATC classification L
Study NCT00947739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camptothecin-20-O-Propionate Hydrate (CZ48)
Description: CZ48 will be administered in successive cohorts of 1 patient per participating site until hints of toxicity (grade 2 or worse adverse events related to the drug) are observed. Then cohort of 3+3 patients will be treated. CZ48 will be administered orally daily for 3 weeks followed by a 1 week rest. (1 course = 4 weeks). No pre-medications will be administered. Patients will be asked to drink 2 liters of fluid daily to flush the bladder.
Study NCT03076333 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: Patient will be scheduled for a pre-treatment PET/MR and proceed to neoadjuvant radiation therapy per the direction of the radiation oncologist. At the end of the second week of radiation therapy the patient will undergo a mid-treatment PET/MR. The patient will the complete their radiation therapy. Four weeks after radiation therapy the patient will undergo a post-treatment PET/MR, and proceed for curative intent surgery at 6-8 weeks post radiation if they are still surgical candidates.
Study NCT03336567 — intervention group
Intervention type: OTHER
Intervention: Telephonic interview
Description: Subjects with cancer and Oncologists will undergo a semi-structured one-to-one telephonic interview for up to 90 and 60 minutes respectively.
Study NCT01893125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNV2197944
Study NCT01893125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01738425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIC-1001; 125 mg oral tablets
Description: Single ascending doses (SAD) from 125 mg to 1000 mg;~Multiple ascending doses from 125 mg to 500 mg, TID over 7 successive days
Study NCT01738425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GIC-1001 matching placebo
Description: Single ascending doses (SAD) \[equivalent to active arm, 125 mg to 1000 mg\]~Multiple ascending doses, TID over 7 successive days \[equivalent to the active arm, 125 mg to 500 mg\]
Study NCT03432715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Student Wellness Champions
Description: Student Wellness Champions participate in a training to, develop a rapport, and build trust with the wellness specialist. SWCs will meet once/week during lunch. The SWC's will receive a health education/ health literacy curriculum in order to be well-versed on the importance of being active and eating healthy foods and how to communicate health information to key stakeholders to enact policy change and to fellow students to enact behavior change. These students will work with the Wellness Specialist and Wellness Champion to implement wellness policies and practices.~Target policies/practices will be presented as a menu of options. The mechanisms used to enact change are based in the tenets of health literacy anchored in nutrition and PA promotion. Components of the curriculum include raising awareness of school system's local wellness policies and improving student skills surrounding the five standards of health literacy, using examples/activities linked to the local wellness policy.
Study NCT03432715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teacher Wellness Champions
Description: Schools will be asked to identify a Wellness Champion (WC), someone at the school who is passionate about creating a healthy school environment. All WC's will be asked to attend a Wellness Champions for Change (WCC) training, led by a Wellness Specialist (health educator part of our study team). The WC's will learn about the skills necessary to make health promoting changes to the School Environment.~Following the WCC training, the Wellness Champion will receive technical assistance from the Wellness Specialist. The Wellness Specialist will work with the Wellness Champion and the school's Wellness Team to conduct a needs assessment, and develop and implement a school action plan. The Wellness Specialist will provide support and resources to the Wellness Champion and the school to help them work towards their goals. All Wellness Champions in a given school system will meet monthly, as a group, with their Wellness Specialist to discuss progress, pitfalls, and successes.
Study NCT02844426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bifid triple viable capsule and pectin
Study NCT02844426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Study NCT03879772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray
Description: intranasal administration
Study NCT05344482 — intervention group
Intervention type: OTHER
Intervention: Secukinumab
Description: Included all the patients treated with secukinumab
Study NCT02501798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Drug: Methylphenidate
Study NCT02501798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo
Study NCT03085030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antioxidant Formula
Description: Antioxidant tablet will be taken by the patients
Study NCT03085030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be taken by the patients
Study NCT04847726 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: contrast enhanced ultrasound
Description: contrast enhanced ultrasound with perfluorobutane and sulfur hexafluoride
Study NCT04847726 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dynamic CT
Description: Participants underwent dynamic CT for hepatic lesion
Study NCT04847726 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liver MRI
Description: Participants underwent liver MRI for hepatic lesion
Study NCT01203280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: icing massage
Description: The intervention, ice massage, was conducted by replacing a bag of crushed ice (100 cc) inside a moistened towel and lightly rubbed over lumbosacral region for 10 minutes. The moisture towel increased the intensity of the cooling sensation more than the dry wrappings
Study NCT04254302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WECARE web platform
Description: The WECARE intervention allows families of children with motor difficulties to access rehabilitation therapists. The primary therapist will be an occupational therapist or a physiotherapist who will have one day a week to deliver the intervention. The therapist will act as case manager to connect families with community-based services available in their region and work, according to a transdisciplinary model, with an interdisciplinary team on a needs-based basis. Patient engagement with the therapists and in the WECARE intervention will be ensured by the collaborative coaching approach used by therapists to attain meaningful motor outcomes, as selected by the primary respondent.
Study NCT04482686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Treatment days 1, 4, and 8